Next 10 |
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
2024-06-17 16:31:49 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town Read the full article on Seeking Alpha For further details see: C...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...
2024-06-05 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selecte...
2024-05-29 06:25:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ),...
2024-05-28 09:21:20 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX slides after early data for Amgen-partnered cancer drug CytomX...
2024-05-27 20:00:04 ET Joseph Catanzaro from Piper Sandler issued a price target of $3.50 for CTMX on 2024-05-27 18:02:00. The adjusted price target was set to $3.50. At the time of the announcement, CTMX was trading at $1.75. The overall price target consensus is at $6....
2024-05-27 19:15:01 ET Piper Sandler analyst issues OVERWEIGHT recommendation for CTMX on May 27, 2024 06:02PM ET. The previous analyst recommendation was Neutral. CTMX was trading at $1.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 20.3% to $0.0699 on volume of 164,902,840 shares Safe and Green Development Corporation (SGD) rose 36.7% to $0.8477 on volume of 100,466,382 shares PROSHARES TRUST (SQQQ) fell 0.6% to $1...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...